Recipharm has struck a deal with Sanofi to buy the French drugmaker’s contract inhalation drug business and plant in the U.K., picking up new capabilities and clients in the process. The Swedish CDMO ...
LONDON, UK, 1 September 2009 - SkyePharma PLC (LSE: SKP) today provides an update following a meeting held with the US Food and Drug Administration (FDA) to discuss the previously announced potential ...
Napp Pharmaceuticals says the UK is the first country in Europe to launch flutiform k-haler, a breath-actuate inhaler for adolescents and adults living with asthma. Napp Pharmaceuticals says the UK is ...
DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Flutiform" report has been added to ResearchAndMarkets.com's offering. Flutiform ([fluticasone propionate + formoterol fumarate]; ...
LONDON, UK, 20 August 2010 - SkyePharma PLC (LSE: SKP) announces that it has regained the United States marketing rights to Flutiform TM, an investigational treatment for persistent asthma in patients ...
flutiform is the first pressurised metered-dose inhaler to combine the ICS, fluticasone propionate, with the fast-acting inhaled LABA, formoterol. 2 flutiform is licensed for asthma maintenance ...
The flutiform k-haler takes its name from a unique kinked valve which removes the need for co-ordination, with only gentle inhalation required to trigger the aerosol. Details of the four flutiform ...
LONDON, UK, 1 December, 2014 - Skyepharma PLC (LSE SKP), the expert oral and inhalation drug development company, today announces that the 120-puff treatment version in strengths of 50/5µg and 125/5µg ...
LONDON, UK, 20 September, 2013 - Skyepharma PLC (LSE SKP), the expert oral and inhalation drug delivery company, announces that the Japanese Ministry of Health, Labour and Welfare ("MHLW"), has ...
- flutiform k-haler is now available in Europe as an asthma treatment for adults and adolescents (aged 12 years and older)[1] - Research indicates that many patients make errors with their inhalers ...
Recipharm, a Swedish drug services firm, will pay $59 million to acquire Sanofi’s inhalation drug business in Holmes Chapel, England. It will get a 125,000-m 2 facility that specializes in metered ...
Rapid changes in the way new drugs are developed and brought to market has put a premium on finding the right partners for success. The breakdown of the old big pharma model which did everything from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback